Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN W CLINTON

Allopathic & Osteopathic Physicians Pediatrics

NPI
1740609601
CMS profile
3710775
Location
PORT LAVACA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$81.75

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $81.75 4

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $60.62 3
Novo Nordisk Inc $21.13 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN W CLINTON

NPI 1740609601 · CMS profile ID 3710775

Allopathic & Osteopathic Physicians / Pediatrics

PORT LAVACA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740609601?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN W CLINTON, NPI 1740609601, CMS profile ID 3710775. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740609601?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN W CLINTON, NPI 1740609601, CMS profile ID 3710775. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740609601?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN W CLINTON, NPI 1740609601, CMS profile ID 3710775, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1740609601?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $81.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $26.5310/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944920717 CMS
GlaxoSmithKline, LLC. $16.9505/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944920715 CMS
Novo Nordisk Inc $21.1302/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898724831 CMS
GlaxoSmithKline, LLC. $17.1401/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944920719 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $84.95 6
PY2020 $86.59 6
PY2021 $24.62 2
PY2022 $81.75 4
PY2023 $164.92 3
PY2024 $16.61 1
PY2025 $75.86 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $755,886.81 71
PY2024 Principal investigator $1,097,775.03 54
PY2023 Recipient $2,903.20 1
PY2023 Principal investigator $441,970.48 78
PY2022 Principal investigator $1,699,691.41 88
PY2021 Principal investigator $4,578,917.10 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $240.03 12/31/2023 Non-covered Recipient Entity
ENSO MB
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991126691
Principal investigator 1 ModernaTX, Inc. $5,050.05 12/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042003571
Principal investigator 1 ModernaTX, Inc. $590.08 12/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042003577
Principal investigator 1 ModernaTX, Inc. $19,623.80 12/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042003583
Principal investigator 1 ModernaTX, Inc. $165.12 12/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042003589
Principal investigator 1 ModernaTX, Inc. $1,915.00 12/22/2023 Non-covered Recipient Entity
ENSO MB LLC D B A VICTORIA CLINICAL RESEARCH GROUP
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1042059779
Principal investigator 1 ModernaTX, Inc. $6,575.00 12/22/2023 Non-covered Recipient Entity
ENSO MB LLC D B A VICTORIA CLINICAL RESEARCH GROUP
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1042059787
Principal investigator 1 ModernaTX, Inc. $510.25 12/20/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1042003601
Principal investigator 1 ModernaTX, Inc. $11,994.57 12/06/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1042003565
Principal investigator 1 ModernaTX, Inc. $881.11 12/06/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1042003595
Principal investigator 1 ModernaTX, Inc. $17,203.55 12/04/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1042003607
Principal investigator 1 GlaxoSmithKline, LLC. $405.90 11/22/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 1127784987
Principal investigator 1 ModernaTX, Inc. $132.48 11/16/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1042003491
Principal investigator 1 ModernaTX, Inc. $12,300.00 11/10/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042003545
Principal investigator 1 ModernaTX, Inc. $3,900.00 11/10/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1042003553
Principal investigator 1 ModernaTX, Inc. $2,017.40 10/25/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003471
Principal investigator 1 ModernaTX, Inc. $66.24 10/19/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1042003465
Principal investigator 1 GlaxoSmithKline, LLC. $811.80 10/18/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127784989
Principal investigator 1 ModernaTX, Inc. $139.38 10/18/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003477
Principal investigator 1 ModernaTX, Inc. $11,270.61 10/06/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042003483
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,100.00 09/27/2023 Non-covered Recipient Entity
ENSO MB
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 991129521
Principal investigator 1 GlaxoSmithKline, LLC. $202.95 09/22/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127784981
Principal investigator 1 ModernaTX, Inc. $881.11 09/15/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003459
Principal investigator 1 AstraZeneca Pharmaceuticals LP $38,265.32 09/08/2023 Non-covered Recipient Entity
ENSO MB
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 991124981
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,100.00 08/30/2023 Non-covered Recipient Entity
ENSO MB
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 991137619
Principal investigator 1 GlaxoSmithKline, LLC. $708.18 08/30/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127784979
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/30/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042003199
Principal investigator 1 GlaxoSmithKline, LLC. $608.85 08/23/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127783816
Principal investigator 1 ModernaTX, Inc. $4,243.74 08/18/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003187
Principal investigator 1 ModernaTX, Inc. $3,789.50 08/18/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003229
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/11/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042003529
Principal investigator 1 ModernaTX, Inc. $5,000.00 08/11/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1042003535
Principal investigator 1 ModernaTX, Inc. $2,100.00 08/04/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003235
Principal investigator 1 ModernaTX, Inc. $6,500.00 08/02/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1042003193
Principal investigator 1 ModernaTX, Inc. $381.21 07/14/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003163
Principal investigator 1 ModernaTX, Inc. $2,578.60 07/14/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003223
Principal investigator 1 GlaxoSmithKline, LLC. $1,578.06 07/12/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127784991
Principal investigator 1 ModernaTX, Inc. $216.15 07/12/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003157
Principal investigator 1 ModernaTX, Inc. $28,255.00 07/12/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003181
Principal investigator 1 ModernaTX, Inc. $3,154.48 07/07/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003169
Principal investigator 1 ModernaTX, Inc. $1,675.52 07/07/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003175
Principal investigator 1 ModernaTX, Inc. $2,202.76 07/03/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003151
Principal investigator 1 ModernaTX, Inc. $450.51 06/28/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003217
Principal investigator 1 ModernaTX, Inc. $3,098.81 06/21/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003132
Principal investigator 1 ModernaTX, Inc. $531.14 06/21/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003137
Principal investigator 1 ModernaTX, Inc. $1,790.31 06/21/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003145
Principal investigator 1 GlaxoSmithKline, LLC. $2,186.91 06/16/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 1127784983
Principal investigator 1 ModernaTX, Inc. $531.14 06/14/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003125
Principal investigator 1 ModernaTX, Inc. $4,328.96 06/07/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003119
Principal investigator 1 ModernaTX, Inc. $5,970.19 06/02/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003113
Principal investigator 1 ModernaTX, Inc. $2,808.38 05/24/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003107
Principal investigator 1 ModernaTX, Inc. $1,635.27 05/19/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003211
Recipient PFIZER INC. $2,903.20 05/18/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046498235
Principal investigator 1 GlaxoSmithKline, LLC. $11,577.06 05/17/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 1127784985
Principal investigator 1 ModernaTX, Inc. $3,216.05 05/17/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003101
Principal investigator 1 ModernaTX, Inc. $2,578.67 05/10/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003095
Principal investigator 1 ModernaTX, Inc. $2,956.54 05/03/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003089
Principal investigator 1 ModernaTX, Inc. $1,612.87 05/01/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042003205
Principal investigator 1 ModernaTX, Inc. $30,169.43 04/26/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003083
Principal investigator 1 ModernaTX, Inc. $2,260.01 04/21/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003075
Principal investigator 1 ModernaTX, Inc. $262.00 04/19/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003069
Principal investigator 1 ModernaTX, Inc. $2,688.78 04/07/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003063
Principal investigator 1 GlaxoSmithKline, LLC. $9,772.29 04/05/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 1006132399
Principal investigator 1 GlaxoSmithKline, LLC. $15,645.96 04/05/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 1006132421
Principal investigator 1 ModernaTX, Inc. $786.00 04/05/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003057
Principal investigator 1 ModernaTX, Inc. $1,500.00 03/29/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042002693
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/29/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1042002699
Principal investigator 1 ModernaTX, Inc. $64,112.97 03/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003045
Principal investigator 1 ModernaTX, Inc. $4,762.11 03/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003051
Principal investigator 1 ModernaTX, Inc. $3,472.35 03/10/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003039
Principal investigator 1 ModernaTX, Inc. $935.86 03/01/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003033
Principal investigator 1 GlaxoSmithKline, LLC. $13,719.42 02/24/2023 Non-covered Recipient Entity
VICTORIA CLINICAL RESEARCH GROUP
PHASE 3B, RANDOMIZED, OBSERVER-BLIND. MULTICENTER STUDY TO ASSESS THE No dispute reported 06/30/2026 1006132411
Principal investigator 1 ModernaTX, Inc. $3,900.07 02/22/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003026
Principal investigator 1 ModernaTX, Inc. $3,251.88 02/15/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003019
Principal investigator 1 ModernaTX, Inc. $2,462.67 02/08/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003013
Principal investigator 1 ModernaTX, Inc. $1,656.00 02/01/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003007
Principal investigator 1 ModernaTX, Inc. $8,386.92 01/25/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042003001
Principal investigator 1 ModernaTX, Inc. $6,499.11 01/18/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002995
Principal investigator 1 ModernaTX, Inc. $2,120.04 01/11/2023 Non-covered Recipient Entity
Victoria Clinical Research Group
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002989